EUVIMEDEUVIMED entdecken
VergleichsstudieÄquivalenzstudieRandomisierte kontrollierte Studie

Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial

Raffaele Piccolo iD, Fiorenzo Simonetti iD, Marisa Avvedimento, Maria Cutillo, Mario Enrico Canonico, Valeria Conti, Giuseppe Gargiulo, Roberta Paolillo iD, Fabrizio Dal Piaz, Amelia Filippelli, Bruno Charlier, Alessandra Spinelli und 5 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 06.11.2024 · 10 (7) · 578-587

DOI: 10.1093/ehjcvp/pvae054 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 18.07.2024. Verfasst von Raffaele Piccolo und 16 weiteren Autor:innen. Beteiligte Einrichtung: D epartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Platelet Aggregation, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although dual antiplatelet therapy with aspirin and a potent P2Y12 receptor inhibitor is currently recommended in patients with acute coronary syndrome (ACS), its use in elderly patients remains challenging. The aim of this trial is to evaluate the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 vs. 90 mg twice daily among elderly patients (≥75 years) with ACS undergoing percutaneous coronary intervention (PCI). Methods and results PLINY The ELDER (NCT04739384) was a randomized, crossover trial testing the non-inferiority of a lower vs. standard dose of ticagrelor with respect to the primary endpoint of P2Y12 inhibition as determined by pre-dose P2Y12 reaction units (PRU) using the VerifyNow-P2Y12 (Accumetrics, San Diego, CA, USA). Other pharmacodynamic tests included light transmittance aggregometry, multiple electrode aggregometry, and response to aspirin. Plasma levels of ticagrelor and its active metabolite AR-C124910XX were also evaluated. A total of 50 patients (mean age 79.6 ± 4.0 years, females 44%) were included in the trial. Ticagrelor 60 mg was non-inferior to ticagrelor 90 mg according to VerifyNow-P2Y12 results (PRU 26.4 ± 32.1 vs. 30.4 ± 39.0; least squares mean difference: −4; 95% confidence interval: −16.27 to 8.06; P for non-inferiority = 0.002). Other pharmacodynamic parameters were similar between the two ticagrelor doses and there were no differences in response to aspirin. Plasma levels of ticagrelor (398.29 ± 312.36 ng/mL vs. 579.57 ± 351.73 ng/mL, P = 0.006) and its active metabolite were significantly lower during treatment with ticagrelor 60 mg.

Conclusion

Although plasma concentrations were lower, ticagrelor 60 mg twice daily provided a similar magnitude of platelet inhibition compared with ticagrelor 90 mg twice daily among elderly patients undergoing PCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelorAgedAged, 80 and overFemaleHumansMaleAge FactorsAspirinBlood PlateletsCross-Over StudiesDrug Administration SchedulePlatelet Function TestsReceptors, Purinergic P2Y12Time FactorsTreatment OutcomeAdenosine

Stichwörter der Autor:innen

Antiplatelet therapyElderlyP2Y12Ticagrelor

Substanzen

AspirinPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12TicagrelorAR C124910XXAdenosineP2RY12 protein, human

Autor:innen und Institutionen

  • D epartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
  • National Centre for Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy.
  • Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Clinical Pharmacology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.

ORCID-Profile: Raffaele Piccolo, Fiorenzo Simonetti, Roberta Paolillo, Giovanni Esposito

Förderung

  • Ministry of Education

Zitieren

APA

Piccolo, R., Simonetti, F., Avvedimento, M., Cutillo, M., Canonico, M. E., Conti, V., Gargiulo, G., Paolillo, R., Dal Piaz, F., Filippelli, A., Charlier, B., Spinelli, A., Cristiano, S., Cirillo, P., Di Serafino, L., Franzone, A., & Esposito, G. (2024). Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. European Heart Journal - Cardiovascular Pharmacotherapy, 10(7), 578-587. https://doi.org/10.1093/ehjcvp/pvae054

Vancouver

Piccolo R, Simonetti F, Avvedimento M, Cutillo M, Canonico ME, Conti V, et al. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(7):578-587. doi:10.1093/ehjcvp/pvae054

BibTeX
@article{Piccolo2024,
  author = {Piccolo, Raffaele and Simonetti, Fiorenzo and Avvedimento, Marisa and Cutillo, Maria and Canonico, Mario Enrico and Conti, Valeria and Gargiulo, Giuseppe and Paolillo, Roberta and Dal Piaz, Fabrizio and Filippelli, Amelia and Charlier, Bruno and Spinelli, Alessandra and Cristiano, Stefano and Cirillo, Plinio and Di Serafino, Luigi and Franzone, Anna and Esposito, Giovanni},
  title = {Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  volume = {10},
  number = {7},
  pages = {578--587},
  doi = {10.1093/ehjcvp/pvae054}
}
Kostenlos starten →